Nanosizing—oral formulation development and biopharmaceutical evaluation F Kesisoglou, S Panmai, Y Wu Advanced drug delivery reviews 59 (7), 631-644, 2007 | 1218 | 2007 |
Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling Y Shono, E Jantratid, N Janssen, F Kesisoglou, Y Mao, M Vertzoni, ... European Journal of Pharmaceutics and Biopharmaceutics 73 (1), 107-114, 2009 | 183 | 2009 |
Understanding the effect of API properties on bioavailability through absorption modeling F Kesisoglou, Y Wu The AAPS journal 10, 516-525, 2008 | 158 | 2008 |
Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans Y Shono, E Jantratid, F Kesisoglou, C Reppas, JB Dressman European journal of pharmaceutics and biopharmaceutics 76 (1), 95-104, 2010 | 146 | 2010 |
In vitro models for the prediction of in vivo performance of oral dosage forms: recent progress from partnership through the IMI OrBiTo collaboration J Butler, B Hens, M Vertzoni, J Brouwers, P Berben, J Dressman, ... European Journal of Pharmaceutics and Biopharmaceutics 136, 70-83, 2019 | 122 | 2019 |
Evolution of choice of solubility and dissolution media after two decades of biopharmaceutical classification system N Bou-Chacra, KJC Melo, IAC Morales, ES Stippler, F Kesisoglou, ... The AAPS journal 19 (4), 989-1001, 2017 | 115 | 2017 |
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network Z Vinarov, B Abrahamsson, P Artursson, H Batchelor, P Berben, ... Advanced drug delivery reviews 171, 289-331, 2021 | 106 | 2021 |
Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development A Mitra, F Kesisoglou Molecular pharmaceutics 10 (11), 3970-3979, 2013 | 101 | 2013 |
Application of nanoparticles in oral delivery of immediate release formulations F Kesisoglou, S Panmai, Y Wu Current Nanoscience 3 (2), 183-190, 2007 | 98 | 2007 |
Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based … C Wagner, E Jantratid, F Kesisoglou, M Vertzoni, C Reppas, JB Dressman European journal of pharmaceutics and biopharmaceutics 82 (1), 127-138, 2012 | 93 | 2012 |
Industry's view on using quality control, biorelevant, and clinically relevant dissolution tests for pharmaceutical development, registration, and commercialization H Grady, D Elder, GK Webster, Y Mao, Y Lin, T Flanagan, J Mann, ... Journal of Pharmaceutical Sciences 107 (1), 34-41, 2018 | 88 | 2018 |
Dissolution and translational modeling strategies toward establishing an in vitro-in vivo link—a workshop summary report T Heimbach, S Suarez-Sharp, M Kakhi, N Holmstock, A Olivares-Morales, ... The AAPS Journal 21 (2), 1-15, 2019 | 86 | 2019 |
Characteristics of the human upper gastrointestinal contents in the fasted state under hypo-and A-chlorhydric gastric conditions under conditions of typical drug–drug … C Litou, M Vertzoni, C Goumas, V Vasdekis, W Xu, F Kesisoglou, ... Pharmaceutical research 33 (6), 1399-1412, 2016 | 86 | 2016 |
Amorphous solid dispersions or prodrugs: complementary strategies to increase drug absorption ACF Rumondor, SS Dhareshwar, F Kesisoglou Journal of pharmaceutical sciences 105 (9), 2498-2508, 2016 | 80 | 2016 |
Use of physiologically based pharmacokinetic (PBPK) modeling for predicting drug-food interactions: an industry perspective AE Riedmaier, K DeMent, J Huckle, P Bransford, C Stillhart, R Lloyd, ... The AAPS journal 22 (6), 1-15, 2020 | 77 | 2020 |
Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds F Kesisoglou, A Mitra The AAPS journal 14 (4), 677-687, 2012 | 77 | 2012 |
3D printed capsules for quantitative regional absorption studies in the GI tract D Smith, Y Kapoor, A Hermans, R Nofsinger, F Kesisoglou, TP Gustafson, ... International Journal of Pharmaceutics 550 (1-2), 418-428, 2018 | 72 | 2018 |
Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis P Vachal, JJ Hale, Z Lu, EC Streckfuss, SG Mills, M MacCoss, DH Yin, ... Journal of medicinal chemistry 49 (11), 3060-3063, 2006 | 72 | 2006 |
PBPK absorption modeling: establishing the in vitro–in vivo link—industry perspective C Stillhart, X Pepin, C Tistaert, D Good, A Van Den Bergh, N Parrott, ... The AAPS Journal 21 (2), 1-13, 2019 | 70 | 2019 |
Food effect projections via physiologically based pharmacokinetic modeling: predictive case studies C Tistaert, T Heimbach, B Xia, N Parrott, TS Samant, F Kesisoglou Journal of pharmaceutical sciences 108 (1), 592-602, 2019 | 67 | 2019 |